论文部分内容阅读
目的 :探讨霍奇金淋巴瘤WHO新分类的可行性 ,并且和Rye分类进行比较。 方法 :将Rye分类的 143例霍奇金淋巴瘤重新按照WHO新分类草案分型 ,比较两种分类各型的构成。所有病人均进行随访。结果 :本组男女之比为 2 3∶1。在结节硬化型中并未见到欧美文献报道的女性多于男性的情况 ;79%的病人发病年龄在 30岁以下 ;90 %病人的首发部位为颈部淋巴结。组织学分型 :结节硬化型 5 5例 (38 5 % ) ,混合细胞型 5 1例 (35 7% ) ,富于淋巴细胞的经典霍奇金淋巴瘤 17例 (12 0 % ) ,具有霍奇金淋巴瘤和大细胞间变性淋巴瘤特点的恶性淋巴瘤 8例 (5 6 % ) ,结节型淋巴细胞为主型 10例 (7 0 % )。随访 :143例中 99例有随访 (70 7% )。WHO分型中以富于淋巴细胞的典型霍奇金淋巴瘤病人的 5年存活率最高 ,达到 5 6 6 % ,其次为结节硬化型 5 5 8% ,混合细胞型 5 1 6 % ,结节型淋巴细胞为主型 40 0 % ,具有间变性大细胞淋巴瘤和霍奇金淋巴特点的恶性淋巴瘤 0。统计学分析表明 ,除Rye分型的结节硬化型和混合细胞型之间差异存在显著性 (P <0 0 5 )外 ,Rye分型的各亚型之间 ,WHO分型各亚型之间 ,以及Rye分型与WHO分型相应亚型病人的存活概率之间差异无显著性。WHO分类草案中的结节硬化型的Ⅰ级和Ⅱ级病人的存活概率之间?
Objective: To explore the feasibility of the new WHO classification of Hodgkin’s lymphoma and compare it with the Rye classification. METHODS: 143 cases of Hodgkin’s lymphoma classified by Rye were re-classified according to the new WHO classification, and the composition of the two classifications was compared. All patients were followed up. Results: The ratio of male to female in this group was 2 3:1. In the nodular sclerosis type, women in the European and European literatures reported no more than men; 79% of patients had an onset age of less than 30 years; 90% of patients had first cervical lymph nodes. Histological type: 55 cases (38.5%) of nodular sclerosis, 51 cases of mixed cell type (35.7%), and 17 cases (120%) of classic Hodgkin’s lymphoma with lymphocytes. Lymphomas of odd lymphomas and large intercellular lymphomas were characterized by malignant lymphoma in 8 cases (56%) and nodular lymphocytes in 10 cases (70%). Follow-up: In 143 cases, 99 cases had a follow-up (70 7%). The five-year survival rate of patients with typical lymphocyte-producing Hodgkin’s lymphoma in WHO classification was the highest, which was 566%, followed by tuberculosclerosis 5 8%, mixed cell type 5-16%. Ganglion type lymphocytes predominantly 40.0%, with anaplastic large cell lymphoma and malignant lymphoma characterized by Hodgkin’s lymphoid 0. Statistical analysis showed that, except for the Rye classification, the difference between the nodular sclerosis type and the mixed cell type was significant (P < 0.05), among the subtypes of the Rye classification, the WHO typed subtypes There was no significant difference in the survival probability between the Rye classification and the corresponding subtypes of the WHO subtype. What is the survival probability of nodular sclerosis type I and II patients in the WHO classification?